If the answer is "we don't know yet", that's what we'll say.
It carries less of the harm a regular cigarette carries (no synthetic pesticide residue, no ammonia chemistry, no 600 additives) and it carries a measured cannabinoid wedge that displaces a portion of the tobacco. But combustion of plant matter into the lungs is intrinsically harmful regardless of what is burning. We will not call it "safe". We call it a harm-reduction format inside a prescription pathway.
No. Mostly Rollie's is dispensed only through pharmacies on a prescription pathway. There is no plan to sell it outside that pathway, ever.
A rolled joint typically contains an unmeasured cannabis dose, ad-hoc tobacco of unknown provenance, and is consumed when the patient decides. A Mostly Rollie's stick contains a specified cannabis dose (~0.07–0.13 g per stick), a verifiably clean tobacco carrier, and is dispensed in a 20-pack on a clinician's prescription with a defined monthly allotment.
It resolves to a public page for that specific pack, showing the cannabis cultivar and the tobacco cultivar that went into it, both with one click upstream to their full Certificates of Analysis on the Cheekyleaf registry. The audit trail is open.
This site collects no patient data. The pharmacy dispensing record is governed by SAHPRA cannabis controlled-substance requirements, not by Mostly Rollie's. See our privacy page.
The prescribers page covers indications, suitability, and the prescription pathway at the concept-stage level. Definitive prescribing information accompanies the SAHPRA registration dossier and is available on request once the dossier is submitted.
Yes, with the caveat that combusted cannabis-plus-tobacco is a distinct route from combusted cannabis alone, vaporised cannabis, or oral cannabis. The harm-reduction case rests on comparison to the unmeasured rolled joint, not to vaporisation or abstinence.
Mostly Rollie's is intended to be contract-manufactured by a SAHPRA s22A licensed cannabis manufacturer with GMP capability. Specific manufacturer and the QA dossier accompany the SAHPRA submission.
No. Mostly Rollie's is at concept stage. The brand, the regulatory positioning, and the supply chain are being assembled. The first pilot is contingent on a SAHPRA manufacturing partner and approved regulatory pathway.
Cheekyleaf is the leaf-provenance registry that sits underneath Mostly Rollie's. Open, neutral, available to any cultivator or grower of cannabis or tobacco who wants their leaf credentialed. Mostly Rollie's is the first commercial product on the Cheekyleaf rail; it will not be the last.
If you are a clinician, a SAHPRA-licensed cannabis manufacturer, an organic tobacco grower, or a regulator, email hello@mostlyrollies.com and tell us which conversation you'd like to have.
Maybe. The launch formulations are anxiety, sleep, and chronic pain. Other formats (smaller pack sizes, alternative cultivars, dose variants) follow the SAHPRA framework if and when clinical evidence supports them.